Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis

  1. Sandra Kümper  Is a corresponding author
  2. Faraz K Mardakheh
  3. Afshan McCarthy
  4. Maggie Yeo
  5. Gordon W Stamp
  6. Angela Paul
  7. Jonathan Worboys
  8. Amine Sadok
  9. Claus Jørgensen
  10. Sabrina Guichard
  11. Christopher J Marshall
  1. Institute of Cancer Research, United Kingdom
  2. Cancer Research UK London Research Institute, United Kingdom
  3. Cancer Research UK Manchester Institute, United Kingdom

Abstract

Rho-associated kinases 1 and 2 (ROCK1/2) are Rho-GTPase effectors that control key aspects of the actin cytoskeleton, but their role in proliferation and cancer initiation or progression is not known. Here we provide evidence that ROCK1 and ROCK2 act redundantly to maintain actomyosin contractility and cell proliferation and that their loss leads to cell-cycle arrest and cellular senescence. This phenotype arises from down-regulation of the essential cell-cycle proteins CyclinA, CKS1 and CDK1. Accordingly, while loss of either Rock1 or Rock2 had no negative impact on tumorigenesis in mouse models of non-small cell lung cancer and melanoma, loss of both blocked tumor formation, as no tumors arise in which both Rock1 and Rock2 have been genetically deleted. Our results reveal an indispensable role for ROCK, yet redundant role for isoforms 1 and 2, in cell cycle progression and tumorigenesis, possibly through the maintenance of cellular contractility.

Article and author information

Author details

  1. Sandra Kümper

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    For correspondence
    sandra.kuemper@icr.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
  2. Faraz K Mardakheh

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Afshan McCarthy

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Maggie Yeo

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Gordon W Stamp

    Experimental Pathology Laboratory, Cancer Research UK London Research Institute, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Angela Paul

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Jonathan Worboys

    Cancer Research UK Manchester Institute, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Amine Sadok

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Claus Jørgensen

    Cancer Research UK Manchester Institute, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Sabrina Guichard

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  11. Christopher J Marshall

    Division of Cancer Biology, Institute of Cancer Research, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Roger Davis, Howard Hughes Medical Institute & University of Massachusetts Medical School, United States

Ethics

Animal experimentation: All animal procedures were approved by the Animal Ethics Committee of the Institute of Cancer Research in accordance with National Home Office regulations under the Animals (Scientific Procedures) Act 1986. The date of approval of the current project license under which this work was carried out was the 07/09/13.

Version history

  1. Received: October 9, 2015
  2. Accepted: January 13, 2016
  3. Accepted Manuscript published: January 14, 2016 (version 1)
  4. Version of Record published: March 7, 2016 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 7,780
    views
  • 1,687
    downloads
  • 117
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Sandra Kümper
  2. Faraz K Mardakheh
  3. Afshan McCarthy
  4. Maggie Yeo
  5. Gordon W Stamp
  6. Angela Paul
  7. Jonathan Worboys
  8. Amine Sadok
  9. Claus Jørgensen
  10. Sabrina Guichard
  11. Christopher J Marshall
(2016)
Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis
eLife 5:e12203.
https://doi.org/10.7554/eLife.12203

Share this article

https://doi.org/10.7554/eLife.12203

Further reading

    1. Cancer Biology
    Sin-Wei Huang, See-Khai Lim ... Kurt Yun Mou
    Research Article

    Certain bacteria demonstrate the ability to target and colonize the tumor microenvironment, a characteristic that positions them as innovative carriers for delivering various therapeutic agents in cancer therapy. Nevertheless, our understanding of how bacteria adapt their physiological condition to the tumor microenvironment remains elusive. In this work, we employed liquid chromatography-tandem mass spectrometry to examine the proteome of E. coli colonized in murine tumors. Compared to E. coli cultivated in the rich medium, we found that E. coli colonized in tumors notably upregulated the processes related to ferric ions, including the enterobactin biosynthesis and iron homeostasis. This finding indicated that the tumor is an iron-deficient environment to E. coli. We also found that the colonization of E. coli in the tumor led to an increased expression of lipocalin 2 (LCN2), a host protein that can sequester the enterobactin. We therefore engineered E. coli in order to evade the nutritional immunity provided by LCN2. By introducing the IroA cluster, the E. coli synthesizes the glycosylated enterobactin, which creates steric hindrance to avoid the LCN2 sequestration. The IroA-E. coli showed enhanced resistance to LCN2 and significantly improved the anti-tumor activity in mice. Moreover, the mice cured by the IroA-E. coli treatment became resistant to the tumor re-challenge, indicating the establishment of immunological memory. Overall, our study underscores the crucial role of bacteria’s ability to acquire ferric ions within the tumor microenvironment for effective cancer therapy.

    1. Cancer Biology
    2. Cell Biology
    Stefanie Schmieder
    Insight

    Mutations in the gene for β-catenin cause liver cancer cells to release fewer exosomes, which reduces the number of immune cells infiltrating the tumor.